2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects model
2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research In Translational Medicine 2019, 67: 51-55. PMID: 30683577, PMCID: PMC7735254, DOI: 10.1016/j.retram.2019.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAgedCytomegalovirusCytomegalovirus InfectionsFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA-DP AntigensHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesRetrospective StudiesRisk FactorsTransplant RecipientsTransplantation ImmunologyTransplantation, HomologousVirus ActivationYoung AdultConceptsHLA-DPB1 mismatchingCMV reactivationOverall survivalRisk of aGVHDRisk of relapseCMV serostatusHLA-DPIncrease riskAllogeneic hematopoietic stem cell transplantationAllogeneic stem cell transplantHematopoietic stem cell transplantationMD Anderson Cancer CenterGVHD target tissuesHLA-DP mismatchesRecipient CMV serostatusRisk of GVHDStem cell transplantStem cell transplantationHLA-DP moleculesAnderson Cancer CenterGVHD incidenceCumulative incidenceCell transplantMultivariable analysisCancer Center